PubMed Health⌕ Search

PubMed · 12161313

Is there a need for resorbable implants or bone substitutes?

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Daniel A Rikli, Pietro Regazzoni, Stephan M Perren. 2002. Is there a need for resorbable implants or bone substitutes?. https://doi.org/10.1016/s0020-1383(02)00126-2

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Photocrosslinked hyaluronic acid hydrogels: natural, biodegradable tissue engineering scaffolds.

Ideally, rationally designed tissue engineering scaffolds promote natural wound healing and regeneration. Therefore, we sought to synthesize a biomimetic hydrogel specifically designed to promote tissue repair and chose hyaluronic acid (HA; also called hyaluronan) as our initial material. Hyaluronic acid is a naturally occurring polymer associated with various cellular processes involved in wound healing, such as angiogenesis. Hyaluronic acid also presents unique advantages: it is easy to produce and modify, hydrophilic and nonadhesive, and naturally biodegradable. We prepared a range of glycidyl methacrylate-HA (GMHA) conjugates, which were subsequently photopolymerized to form crosslinked GMHA hydrogels. A range of hydrogel degradation rates was achieved as well as a corresponding, modest range of material properties (e.g., swelling, mesh size). Increased amounts of conjugated methacrylate groups corresponded with increased crosslink densities and decreased degradation rates and yet had an insignificant effect on human aortic endothelial cell cytocompatibility and proliferation. Rat subcutaneous implants of the GMHA hydrogels showed good biocompatibility, little inflammatory response, and similar levels of vascularization at the implant edge compared with those of fibrin positive controls. Therefore, these novel GMHA hydrogels are suitable for modification with adhesive peptide sequences (e.g., RGD) and use in a variety of wound-healing applications.

Absorbable Implants↗

A dual constant-composition titration system as an in vitro resorption model for comparing dissolution rates of calcium phosphate biomaterials.

It has been postulated that the in vivo resorption rates of calcium-phosphate bone-graft materials are closely related to their dissolution rates in demineralizing solutions having ionic compositions mimicking the acidic environment produced by osteoclasts. Thus, it should be possible to use an in vitro model to produce dissolution-rate data of calcium-phosphate materials as a starting point for predicting in vivo resorption properties. Direct pH measurements of the extracellular fluid from bone-resorbing cells showed that the pH was as low as 3. In the present study, a dual constant-composition dissolution system was used as an in vitro resorption model to compare dissolution rates of different calcium-phosphate materials. NIST standard reference hydroxyapatite (HA), dicalcium-phosphate dihydrate (DCPD), and calcium-phosphate cement (CPC) discs of known dimensions (6-mm d x 3-mm h) were allowed to dissolve at 37 degrees C in a solution that had an inorganic composition similar to that of serum ([Ca] = 1.15 mmol/l; [P] = 1.2 mmol/l; [KCl] = 133 mmol/l) and a pH of 3.0. A Ca ion-specific electrode and a pH electrode were used to control the addition of titrants to compensate for the increases in calcium and phosphate concentrations, respectively, in the demineralizing solution. The rate and stoichiometry (Ca/P molar ratio) of dissolution were obtained from the titration data. Each solid dissolved at an approximately constant rate during the dissolution process. The dissolution rates, expressed in mg cm(-2) min(-1), (mean +/- standard deviation, n = 5) were for HA: 6.58 +/- 1.22; DCPD: 21.0 +/- 2.6; and CPC: 8.21 +/- 0.73. DCPD dissolved three times faster than HA (p < 0.05). CPC dissolved 1.2 times faster than HA but the difference was not statistically significant (p > 0.05). This model can be used to study the rate and stoichiometry of dissolution of calcium-phosphate bone-graft materials and coatings under a wide range of mineral saturation conditions.

Absorbable Implants↗

Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial.

PURPOSE: This New Approaches to Brain Tumor Therapy CNS Consortium study sought to determine the maximum-tolerated dose (MTD) of carmustine (BCNU) that can be implanted in biodegradable polymers following resection of recurrent high-grade gliomas and the systemic BCNU exposure with increasing doses of interstitial BCNU. PATIENTS AND METHODS: Forty-four adults underwent tumor debulking and polymer placement. Six patients per dose level were studied using polymers with 6.5%, 10%, 14.5%, 20%, and 28% BCNU by weight. Toxicities were assessed 1 month after implantation by a safety monitoring committee to determine whether subsequent escalations should occur. Nine additional patients were studied at the MTD to confirm safety. BCNU blood levels were obtained before and after polymer implantation. RESULTS: No dose-limiting toxicities were identified at the 6.5%, 10%, or 14.5% dose levels, although difficulties with wound healing, seizures, and brain edema were noted. At the 20% dose, these effects seemed more prominent, and six additional patients were treated at this dose and tolerated treatment well. Three of four patients receiving the 28% polymers developed severe brain edema and seizures, and accrual to this cohort was stopped. Nine additional patients received 20% polymer, confirming this as the MTD. Maximum BCNU plasma concentrations with the 20% loaded polymers were 27 ng/mL. Overall median survival was 251 days. CONCLUSION: The MTD of BCNU delivered in polymer to the surgical cavity is 20%. This polymer provides five times more BCNU than standard commercially available BCNU polymers and results in minimal systemic BCNU exposure. Additional studies are needed to establish the efficacy of high-dose BCNU polymers.

Absorbable Implants↗